036005178	036005178	CD	B-NP	O
|	|	NNP	I-NP	O
EOMCOA	EOMCOA	NNP	I-NP	O
|	|	VBD	B-VP	O
12362214	12362214	CD	B-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
9112528	9112528	CD	B-NP	O
|	|	CC	I-NP	O
9/4/2004	9/4/2004	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
UNSTABLE	UNSTABLE	NNP	I-NP	I-protein
ANGINA	ANGINA	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Signed	Signed	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
6/29/2004	6/29/2004	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
5/11/2004	5/11/2004	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
EUSEBIO	EUSEBIO	NN	B-NP	O
JUDE	JUDE	NN	I-NP	O
MONFORE	MONFORE	NN	I-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
Congestive	Congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

PRINCIPAL	PRINCIPAL	JJ	B-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
DIAGNOSES	DIAGNOSES	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Congestive	Congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Diastolic	Diastolic	JJ	B-NP	O
dysfunction	dysfunction	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Hypertension	Hypertension	NN	B-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Diabetes	Diabetes	NN	B-NP	O
mellitus	mellitus	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Serratia	Serratia	NNP	B-NP	O
UTI	UTI	NNP	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Chronic	Chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
dysfunction	dysfunction	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Dyslipidemia	Dyslipidemia	NN	B-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Coronary	Coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Mild	Mild	JJ	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
hypertension	hypertension	NN	I-NP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Mitral	Mitral	JJ	B-NP	O
regurgitation	regurgitation	NN	I-NP	O
.	.	.	O	O

ALLERGIES	ALLERGIES	NNS	B-NP	O
:	:	:	O	O
Penicillins	Penicillin	NNS	B-NP	B-protein
.	.	.	O	O

BRIEF	BRIEF	NN	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
pleasant	pleasant	JJ	I-NP	O
78-year-old	78-year-old	JJ	I-NP	O
gentleman	gentleman	NN	I-NP	O
who	who	WP	B-NP	O
presents	present	VBZ	B-VP	O
with	with	IN	B-PP	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
and	and	CC	O	O
paroxysmal	paroxysmal	JJ	B-NP	O
nocturnal	nocturnal	JJ	I-NP	O
dyspnea	dyspnea	NN	I-NP	O
for	for	IN	B-PP	O
approximately	approximately	RB	B-NP	O
three	three	CD	I-NP	O
weeks	week	NNS	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
MI	MI	NN	I-NP	O
in	in	IN	B-PP	O
1994	1994	CD	B-NP	O
and	and	CC	O	O
four-vessel	four-vessel	JJ	B-NP	O
CABG	CABG	NN	I-NP	O
with	with	IN	B-PP	O
subsequently	subsequently	RB	B-NP	O
placed	place	VBN	I-NP	O
five	five	CD	I-NP	O
stents	stent	NNS	I-NP	O
in	in	IN	B-PP	O
2002	2002	CD	B-NP	O
for	for	IN	B-PP	O
graft	graft	NN	B-NP	O
and	and	CC	O	O
native	native	JJ	B-NP	O
vessel	vessel	NN	I-NP	O
stenosis	stenosis	NN	I-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
chronic	chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
baseline	baseline	NN	I-NP	O
creatinine	creatinine	NN	I-NP	O
of	of	IN	B-PP	O
2.8	2.8	CD	B-NP	O
,	,	,	O	O
diabetes	diabetes	NN	B-NP	B-protein
mellitus	mellitus	NN	I-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
insulin	insulin	NN	I-NP	I-protein
dependent	dependent	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
,	,	,	O	O
hyperlipidemia	hyperlipidemia	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
a	a	DT	B-NP	O
pace	pace	NN	I-NP	O
maker	maker	NN	I-NP	O
for	for	IN	B-PP	O
symptomatic	symptomatic	JJ	B-NP	O
bradycardia	bradycardia	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
is	be	VBZ	B-VP	O
presented	present	VBN	I-VP	O
with	with	IN	B-PP	O
three	three	CD	B-NP	O
weeks	week	NNS	I-NP	O
of	of	IN	B-PP	O
increasing	increase	VBG	B-VP	O
orthopnea	orthopnea	NN	B-NP	O
,	,	,	O	O
dyspnea	dyspnea	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
paroxysmal	paroxysmal	JJ	B-NP	O
nocturnal	nocturnal	JJ	I-NP	O
dyspnea	dyspnea	NN	I-NP	O
with	with	IN	B-PP	O
rare	rare	JJ	B-NP	O
chest	chest	NN	I-NP	O
tightness	tightness	NN	I-NP	O
without	without	IN	B-PP	O
radiation	radiation	NN	B-NP	O
and	and	CC	I-NP	O
onset	onset	NN	I-NP	O
of	of	IN	B-PP	O
symptoms	symptom	NNS	B-NP	O
mainly	mainly	RB	B-ADVP	O
while	while	IN	B-SBAR	O
recumbent	recumbent	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
presents	present	VBZ	B-VP	O
after	after	IN	B-PP	O
coming	come	VBG	B-VP	O
to	to	TO	B-PP	O
an	an	DT	B-NP	O
outside	outside	JJ	I-NP	O
hospital	hospital	NN	I-NP	O
with	with	IN	B-PP	O
three	three	CD	B-NP	O
to	to	TO	I-NP	O
four	four	CD	I-NP	O
days	day	NNS	I-NP	O
of	of	IN	B-PP	O
these	these	DT	B-NP	O
worsening	worsen	VBG	I-NP	O
symptoms	symptom	NNS	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
transferred	transfer	VBN	I-VP	O
to	to	TO	B-PP	O
Baspit	Baspit	NNP	B-NP	O
Hospital	Hospital	NNP	I-NP	O
where	where	WRB	B-ADVP	O
he	he	PRP	B-NP	O
received	receive	VBD	B-VP	O
most	most	JJS	B-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
cardiac	cardiac	JJ	I-NP	O
care	care	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
these	these	DT	B-NP	O
worsening	worsen	VBG	I-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
symptoms	symptom	NNS	I-NP	O
after	after	IN	B-PP	O
a	a	DT	B-NP	O
trip	trip	NN	I-NP	O
to	to	TO	B-PP	O
I	I	NNP	B-NP	O
Hwy	Hwy	NNP	I-NP	O
,	,	,	O	O
Ny	Ny	NNP	B-NP	O
Vale	Vale	NNP	I-NP	O
,	,	,	O	O
Michigan	Michigan	NNP	B-NP	O
34152	34152	CD	I-NP	O
,	,	,	O	O
some	some	DT	B-NP	O
dietary	dietary	JJ	I-NP	O
indiscretion	indiscretion	NN	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
five-pound	five-pound	JJ	I-NP	B-protein
weight	weight	NN	I-NP	I-protein
gain	gain	NN	I-NP	I-protein
.	.	.	O	O

He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
had	have	VBN	I-VP	O
no	no	DT	B-NP	O
syncope	syncope	NN	I-NP	O
,	,	,	O	O
palpitations	palpitation	NNS	B-NP	O
,	,	,	O	O
but	but	CC	O	O
has	have	VBZ	B-VP	O
had	have	VBN	I-VP	O
some	some	DT	B-NP	O
mild	mild	JJ	I-NP	O
nausea	nausea	NN	I-NP	O
without	without	IN	B-PP	O
emesis	emesis	NN	B-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
the	the	DT	B-NP	O
outside	outside	JJ	I-NP	O
hospital	hospital	NN	I-NP	O
when	when	WRB	B-ADVP	O
he	he	PRP	B-NP	O
presented	present	VBD	B-VP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
EKG	EKG	NN	I-NP	B-protein
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
baseline	baseline	NN	I-NP	O
left	leave	VBD	B-VP	O
bundle-branch	bundle-branch	NN	B-NP	O
block	block	NN	I-NP	O
and	and	CC	O	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
troponin	troponin	NN	I-NP	O
of	of	IN	B-PP	O
0.13	0.13	CD	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
some	some	DT	B-NP	O
Lasix	Lasix	NNP	I-NP	O
and	and	CC	O	O
had	have	VBD	B-VP	O
echocardiogram	echocardiogram	NN	B-NP	O
,	,	,	O	O
had	have	VBD	B-VP	O
initially	initially	RB	I-VP	O
revealed	reveal	VBN	I-VP	O
an	an	DT	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
35	35	CD	B-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
transferred	transfer	VBN	I-VP	O
to	to	TO	B-PP	O
Me	Me	NNP	B-NP	O
Ale	Ale	NNP	I-NP	O
Firstray	Firstray	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
,	,	,	O	O
started	start	VBD	B-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
nitroglycerin	nitroglycerin	NN	I-NP	B-protein
drip	drip	NN	I-NP	I-protein
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
a	a	DT	B-NP	O
heparin	heparin	NN	I-NP	O
drip	drip	NN	I-NP	O
for	for	IN	B-PP	O
presumed	presume	VBN	B-NP	O
coronary	coronary	JJ	I-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
repeat	repeat	NN	I-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
showed	show	VBD	B-VP	O
an	an	DT	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
50	50	CD	B-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
anterior	anterior	JJ	B-NP	O
wall	wall	NN	I-NP	O
distal	distal	JJ	I-NP	O
dyskinesis	dyskinesis	NN	I-NP	O
from	from	IN	B-PP	O
an	an	DT	B-NP	O
old	old	JJ	I-NP	O
myocardial	myocardial	JJ	I-NP	O
infarction	infarction	NN	I-NP	O
and	and	CC	O	O
moderate-to-severe	moderate-to-severe	JJ	B-NP	O
mitral	mitral	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
that	that	IN	B-SBAR	O
he	he	PRP	B-NP	O
received	receive	VBD	B-VP	O
in	in	IN	B-PP	O
1/8	1/8	CD	B-NP	O
.	.	.	O	O

Upon	Upon	IN	B-PP	O
presentation	presentation	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
,	,	,	O	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
heart	heart	NN	I-NP	O
rate	rate	NN	I-NP	O
of	of	IN	B-PP	O
82	82	CD	B-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
of	of	IN	B-PP	O
138/64	138/64	CD	B-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
sating	sate	VBG	I-VP	O
96	96	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
5	5	CD	B-NP	O
liters	liter	NNS	I-NP	O
of	of	IN	B-PP	O
nasal	nasal	JJ	B-NP	O
canula	canula	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
jugular	jugular	JJ	I-NP	O
venous	venous	JJ	I-NP	O
pressure	pressure	NN	I-NP	O
was	be	VBD	B-VP	O
7	7	CD	B-NP	O
cm	cm	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
lungs	lung	NNS	I-NP	O
had	have	VBD	B-VP	O
rales	rale	NNS	B-NP	O
bilaterally	bilaterally	RB	B-ADVP	O
,	,	,	O	O
approximately	approximately	RB	B-NP	O
half	half	JJ	I-NP	O
way	way	NN	I-NP	O
up	up	IN	B-ADVP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
dullness	dullness	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
heart	heart	NN	I-NP	O
was	be	VBD	B-VP	O
regular	regular	JJ	B-NP	O
rate	rate	NN	I-NP	O
and	and	CC	I-NP	O
rhythm	rhythm	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
3/6	3/6	CD	I-NP	O
holosystolic	holosystolic	JJ	I-NP	O
murmur	murmur	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
apex	apex	NN	I-NP	O
with	with	IN	B-PP	O
radiation	radiation	NN	B-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
axilla	axilla	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
S3	S3	NN	I-NP	B-protein
,	,	,	O	O
and	and	CC	O	O
no	no	DT	B-NP	O
S4	S4	NN	I-NP	B-protein
.	.	.	O	O

His	His	PRP$	B-NP	O
abdomen	abdomen	NN	I-NP	O
was	be	VBD	B-VP	O
mildly	mildly	RB	I-VP	O
distended	distend	VBN	I-VP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
fluid	fluid	NN	I-NP	O
waves	wave	NNS	I-NP	O
and	and	CC	O	O
positive	positive	JJ	B-NP	O
bowel	bowel	NN	I-NP	O
sounds	sound	NNS	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
extremities	extremity	NNS	I-NP	O
were	be	VBD	B-VP	O
warm	warm	JJ	B-ADJP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
pedal	pedal	JJ	I-NP	O
edema	edema	NN	I-NP	O
and	and	CC	I-NP	O
1	1	CD	I-NP	O
+	+	SYM	I-NP	O
dorsalis	dorsalis	NN	I-NP	O
pedis	pedis	NN	I-NP	O
pulses	pulse	VBZ	B-VP	O
bilaterally	bilaterally	RB	B-ADVP	O
.	.	.	O	O

EKG	EKG	NN	B-NP	O
at	at	IN	B-PP	O
Baneers	Baneers	NNP	B-NP	O
Hospital	Hospital	NNP	I-NP	O
revealed	reveal	VBD	B-VP	O
a	a	DT	B-NP	O
dual	dual	JJ	I-NP	O
chamber	chamber	NN	I-NP	O
pacemaker	pacemaker	NN	I-NP	O
with	with	IN	B-PP	O
left	left	JJ	B-NP	O
bundle-branch	bundle-branch	NN	I-NP	O
pattern	pattern	NN	I-NP	O
and	and	CC	O	O
no	no	DT	B-NP	O
significant	significant	JJ	I-NP	O
ST	ST	NN	I-NP	O
wave	wave	NN	I-NP	O
changes	change	NNS	I-NP	O
and	and	CC	O	O
an	an	DT	B-NP	O
occasional	occasional	JJ	I-NP	O
PVC	PVC	NN	I-NP	O
.	.	.	O	O

ADMISSION	ADMISSION	NN	B-NP	O
LABORATORIES	LABORATORIES	NN	I-NP	O
:	:	:	O	O
Significant	Significant	JJ	B-ADJP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
creatinine	creatinine	NN	I-NP	O
of	of	IN	B-PP	O
3.1	3.1	CD	B-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
BUN	BUN	NN	I-NP	O
of	of	IN	B-PP	O
76	76	CD	B-NP	O
,	,	,	O	O
potassium	potassium	NN	B-NP	O
of	of	IN	B-PP	O
5.3	5.3	CD	B-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
hematocrit	hematocrit	NN	I-NP	B-protein
was	be	VBD	B-VP	I-protein
29.4	29.4	CD	B-NP	I-protein
,	,	,	O	O
and	and	CC	O	O
PT-T	PT-T	NN	B-NP	B-protein
was	be	VBD	B-VP	O
56	56	CD	B-NP	O
on	on	IN	B-PP	O
heparin	heparin	NN	B-NP	O
drip	drip	NN	I-NP	O
.	.	.	O	O

BRIEF	BRIEF	NN	B-NP	O
RESUME	RESUME	NN	I-NP	O
OF	OF	IN	B-PP	O
HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Ischemia	Ischemia	NNP	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
an	an	DT	B-NP	O
extensive	extensive	JJ	I-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
is	be	VBZ	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
,	,	,	O	O
Plavix	Plavix	NN	B-NP	O
,	,	,	O	O
low	low	JJ	B-NP	O
dose	dose	NN	I-NP	O
beta-blocker	beta-blocker	NN	I-NP	O
with	with	IN	B-PP	O
carvedilol	carvedilol	NN	B-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
ACE	ACE	NN	B-NP	O
inhibitor	inhibitor	NN	I-NP	O
and	and	CC	I-NP	O
statin	statin	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
initially	initially	RB	B-ADVP	O
came	come	VBD	B-VP	O
in	in	RP	B-PRT	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
troponin	troponin	NN	I-NP	O
of	of	IN	B-PP	O
0.13	0.13	CD	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
as	as	IN	B-SBAR	O
demand	demand	NN	B-NP	O
ischemia	ischemia	NN	I-NP	O
related	relate	VBN	B-VP	O
to	to	TO	B-PP	O
systemic	systemic	JJ	B-NP	O
hypertension	hypertension	NN	I-NP	O
and	and	CC	O	O
pulmonary	pulmonary	JJ	B-NP	O
hypertension	hypertension	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
enzymes	enzyme	NNS	I-NP	B-protein
trended	trend	VBD	B-VP	O
down	down	RB	B-ADVP	O
and	and	CC	O	O
were	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
after	after	IN	B-PP	O
the	the	DT	B-NP	O
initial	initial	JJ	I-NP	O
check	check	NN	I-NP	O
.	.	.	O	O

Eventually	Eventually	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
received	receive	VBD	B-VP	O
48	48	CD	B-NP	O
hours	hour	NNS	I-NP	O
of	of	IN	B-PP	O
intravenous	intravenous	JJ	B-NP	O
heparin	heparin	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
IV	IV	CD	B-NP	O
nitroglycerin	nitroglycerin	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
chest	chest	NN	B-NP	O
pain	pain	NN	I-NP	O
free	free	JJ	B-ADJP	O
.	.	.	O	O

At	At	IN	B-PP	O
this	this	DT	B-NP	O
point	point	NN	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
received	receive	VBD	B-VP	O
an	an	DT	B-NP	O
Adenosine	Adenosine	NN	I-NP	O
MIBI	MIBI	NN	I-NP	O
nuclear	nuclear	JJ	I-NP	O
study	study	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
revealed	reveal	VBD	B-VP	O
a	a	DT	B-NP	O
known	known	JJ	I-NP	O
distal	distal	JJ	I-NP	O
anterior	anterior	JJ	I-NP	O
wall	wall	NN	I-NP	O
scar	scar	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
very	very	RB	I-NP	O
small	small	JJ	I-NP	O
surrounding	surround	VBG	I-NP	O
region	region	NN	I-NP	O
of	of	IN	B-PP	O
reversible	reversible	JJ	B-NP	O
ischemia	ischemia	NN	I-NP	O
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
nonrevascularizable	nonrevascularizable	JJ	B-ADJP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
optimum	optimum	JJ	B-NP	O
medical	medical	JJ	I-NP	O
management	management	NN	I-NP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
caveat	caveat	NN	I-NP	O
that	that	IN	B-SBAR	O
cardiac	cardiac	JJ	B-NP	O
catheterization	catheterization	NN	I-NP	O
in	in	IN	B-PP	O
this	this	DT	B-NP	O
gentleman	gentleman	NN	I-NP	O
who	who	WP	B-NP	O
had	have	VBD	B-VP	O
already	already	RB	I-VP	O
had	have	VBN	I-VP	O
previous	previous	JJ	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
renal	renal	JJ	B-NP	O
dysfunction	dysfunction	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
creatinine	creatinine	NN	I-NP	O
rise	rise	NN	I-NP	O
to	to	TO	B-PP	O
nearly	nearly	RB	B-NP	O
7	7	CD	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
dye	dye	NN	I-NP	O
load	load	NN	I-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
warranted	warrant	VBN	I-VP	O
nor	nor	CC	I-VP	O
indicated	indicate	VBN	I-VP	O
at	at	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
.	.	.	O	O

By	By	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
ambulating	ambulate	VBG	I-VP	O
halls	hall	NNS	B-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
chest	chest	NN	B-NP	O
tightness	tightness	NN	I-NP	O
free	free	JJ	B-ADJP	O
.	.	.	O	O

Coronary	Coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
a	a	DT	B-NP	O
noncontributory	noncontributory	JJ	I-NP	B-protein
factor	factor	NN	I-NP	I-protein
to	to	TO	B-PP	O
his	his	PRP$	B-NP	O
CHF	CHF	NN	I-NP	O
exacerbation	exacerbation	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Pump	Pump	NNP	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
45	45	CD	B-NP	O
%	%	NN	I-NP	O
upon	upon	IN	B-PP	O
admission	admission	NN	B-NP	O
with	with	IN	B-PP	O
moderate-to-severe	moderate-to-severe	JJ	B-NP	O
mitral	mitral	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
diuresed	diurese	VBN	I-VP	O
approximately	approximately	RB	B-NP	O
3	3	CD	I-NP	O
liters	liter	NNS	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
combination	combination	NN	I-NP	O
of	of	IN	B-PP	O
Lasix	Lasix	NNP	B-NP	O
and	and	CC	I-NP	O
Natrecor	Natrecor	NNP	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
this	this	DT	B-NP	O
point	point	NN	I-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
edema	edema	NN	I-NP	O
had	have	VBD	B-VP	O
resolved	resolve	VBN	I-VP	O
and	and	CC	O	O
his	his	PRP$	B-NP	O
oxygen	oxygen	NN	I-NP	O
requirement	requirement	NN	I-NP	O
was	be	VBD	B-VP	O
decreased	decrease	VBN	I-VP	O
.	.	.	O	O

Given	Give	VBN	B-PP	O
the	the	DT	B-NP	O
fact	fact	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
tenuous	tenuous	JJ	I-NP	O
renal	renal	JJ	I-NP	O
status	status	NN	I-NP	O
,	,	,	O	O
we	we	PRP	B-NP	O
wanted	want	VBD	B-VP	O
to	to	TO	I-VP	O
avoid	avoid	VB	I-VP	O
further	further	JJ	B-NP	O
diuresis	diuresis	NN	I-NP	O
or	or	CC	O	O
after-load	after-load	JJ	B-NP	O
reduction	reduction	NN	I-NP	O
until	until	IN	B-SBAR	O
we	we	PRP	B-NP	O
knew	know	VBD	B-VP	O
exactly	exactly	RB	B-NP	O
what	what	WP	I-NP	O
his	his	PRP$	B-NP	O
right	right	NN	I-NP	O
and	and	CC	O	O
left	leave	VBD	B-VP	O
heart	heart	NN	B-NP	O
filling	filling	NN	I-NP	O
pressures	pressure	NNS	I-NP	O
were	be	VBD	B-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
taken	take	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Cardiovascular	Cardiovascular	NNP	I-NP	O
Diagnostic	Diagnostic	NNP	I-NP	O
Laboratory	Laboratory	NNP	I-NP	O
and	and	CC	O	O
received	receive	VBD	B-VP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
heart	heart	NN	I-NP	O
catheterization	catheterization	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
capillary	capillary	JJ	I-NP	O
wedge	wedge	NN	I-NP	O
pressure	pressure	NN	I-NP	O
was	be	VBD	B-VP	O
determined	determine	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
16	16	CD	B-NP	O
and	and	CC	O	O
his	his	PRP$	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
artery	artery	NN	I-NP	O
pressure	pressure	NN	I-NP	O
56/18	56/18	CD	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
RA	RA	NN	I-NP	B-protein
pressure	pressure	NN	I-NP	I-protein
was	be	VBD	B-VP	I-protein
8	8	CD	B-NP	I-protein
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
some	some	DT	B-NP	O
initial	initial	JJ	I-NP	O
false	false	JJ	I-NP	O
elevation	elevation	NN	I-NP	O
because	because	IN	B-PP	O
of	of	IN	I-PP	O
inadequate	inadequate	JJ	B-NP	O
sedation	sedation	NN	I-NP	O
while	while	IN	B-SBAR	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
cath	cath	NN	I-NP	O
lab	lab	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
transferred	transfer	VBN	I-VP	O
for	for	IN	B-PP	O
48	48	CD	B-NP	O
hours	hour	NNS	I-NP	O
of	of	IN	B-PP	O
tailored	tailor	VBN	B-NP	O
therapy	therapy	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Cardiac	Cardiac	NNP	I-NP	O
Care	Care	NNP	I-NP	O
Unit	Unit	NNP	I-NP	O
where	where	WRB	B-ADVP	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
artery	artery	NN	I-NP	O
catheter	catheter	NN	I-NP	O
in	in	IN	B-PP	O
place	place	NN	B-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
this	this	DT	B-NP	O
point	point	NN	I-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
after-load	after-load	JJ	I-NP	O
reduction	reduction	NN	I-NP	O
was	be	VBD	B-VP	O
maximized	maximize	VBN	I-VP	O
with	with	IN	B-PP	O
combination	combination	NN	B-NP	O
of	of	IN	B-PP	O
hydralazine	hydralazine	NN	B-NP	O
and	and	CC	I-NP	O
Isordil	Isordil	NN	I-NP	O
with	with	IN	B-PP	O
good	good	JJ	B-NP	O
effect	effect	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
decreased	decrease	VBD	B-VP	O
with	with	IN	B-PP	O
after-load	after-load	JJ	B-NP	O
reduction	reduction	NN	I-NP	O
to	to	TO	B-PP	O
2.7	2.7	CD	B-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
symptoms	symptom	NNS	I-NP	O
improved	improve	VBN	B-VP	O
and	and	CC	O	O
we	we	PRP	B-NP	O
were	be	VBD	B-VP	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
diurese	diurese	VB	I-VP	O
another	another	DT	B-NP	O
2	2	CD	I-NP	O
liters	liter	NNS	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
.	.	.	O	O

By	By	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
actually	actually	RB	I-VP	O
becoming	become	VBG	I-VP	O
hypertensive	hypertensive	JJ	B-ADJP	O
again	again	RB	B-ADVP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
amlodipine	amlodipine	NN	B-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
calcium	calcium	NN	I-NP	O
channel	channel	NN	I-NP	O
blocker	blocker	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
he	he	PRP	B-NP	O
has	have	VBZ	B-VP	O
tolerated	tolerate	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
exposed	expose	VBN	I-VP	O
to	to	TO	B-PP	O
ACE	ACE	NN	B-NP	O
inhibition	inhibition	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
and	and	CC	O	O
is	be	VBZ	B-VP	O
currently	currently	RB	B-ADVP	O
not	not	RB	O	O
on	on	IN	B-PP	O
an	an	DT	B-NP	O
ACE	ACE	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
had	have	VBN	I-VP	O
a	a	DT	B-NP	O
rise	rise	NN	I-NP	O
in	in	IN	B-PP	O
his	his	PRP$	B-NP	O
potassium	potassium	NN	I-NP	O
to	to	TO	B-PP	O
5.5	5.5	CD	B-NP	O
on	on	IN	B-PP	O
ACE	ACE	NN	B-NP	O
inhibition	inhibition	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
basis	basis	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
future	future	NN	I-NP	O
,	,	,	O	O
we	we	PRP	B-NP	O
would	would	MD	B-VP	O
suggest	suggest	VB	I-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
have	have	VBP	B-VP	O
a	a	DT	B-NP	O
trial	trial	NN	I-NP	O
of	of	IN	B-PP	O
ACE	ACE	NN	B-NP	O
or	or	CC	I-NP	O
ARB	ARB	NN	I-NP	B-protein
to	to	TO	B-VP	O
optimize	optimize	VB	I-VP	O
his	his	PRP$	B-NP	O
after-load	after-load	JJ	I-NP	O
reduction	reduction	NN	I-NP	O
and	and	CC	O	O
neurohormonal	neurohormonal	JJ	B-NP	O
activation	activation	NN	I-NP	O
with	with	IN	B-PP	O
his	his	PRP$	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
regimen	regimen	NN	I-NP	O
includes	include	VBZ	B-VP	O
standing	stand	VBG	B-NP	O
Lasix	Lasix	NNP	I-NP	O
,	,	,	I-NP	O
carvedilol	carvedilol	NN	I-NP	O
,	,	,	I-NP	O
Isordil	Isordil	NN	I-NP	O
and	and	CC	I-NP	O
hydralazine	hydralazine	NN	I-NP	O
,	,	,	O	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
digoxin	digoxin	NN	B-NP	O
for	for	IN	B-PP	O
symptomatic	symptomatic	JJ	B-NP	O
improvement	improvement	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Rhythm	Rhythm	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
dual-chambered	dual-chambered	JJ	I-NP	O
pacemaker	pacemaker	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
telemetry	telemetry	NN	B-NP	O
throughout	throughout	IN	B-PP	O
his	his	PRP$	B-NP	O
hospital	hospital	NN	I-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
electrolytes	electrolyte	NNS	I-NP	O
were	be	VBD	B-VP	O
replete	replete	JJ	B-ADJP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
is	be	VBZ	B-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
low-dose	low-dose	JJ	I-NP	B-protein
beta-blocker	beta-blocker	NN	I-NP	I-protein
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
few	few	JJ	I-NP	O
rounds	round	NNS	I-NP	O
of	of	IN	B-PP	O
nonsustained	nonsustained	JJ	B-NP	O
ventricular	ventricular	JJ	I-NP	O
tachycardia	tachycardia	NN	I-NP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
8	8	CD	I-NP	O
beats	beat	NNS	I-NP	O
every	every	DT	B-NP	O
time	time	NN	I-NP	O
during	during	IN	B-PP	O
his	his	PRP$	B-NP	O
hospital	hospital	NN	I-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
not	not	RB	O	O
at	at	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
a	a	DT	B-NP	O
candidate	candidate	NN	I-NP	O
for	for	IN	B-PP	O
resynchronization	resynchronization	NN	B-NP	O
biventricular	biventricular	JJ	I-NP	O
pacer	pacer	NN	I-NP	O
therapy	therapy	NN	I-NP	O
because	because	IN	B-SBAR	O
his	his	PRP$	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
45	45	CD	B-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
even	even	RB	B-SBAR	O
if	if	IN	I-SBAR	O
his	his	PRP$	B-NP	O
QRS	QRS	NN	I-NP	B-protein
interval	interval	NN	I-NP	O
is	be	VBZ	B-VP	O
greater	great	JJR	B-NP	O
than	than	IN	I-NP	O
150	150	CD	I-NP	O
ms.	ms.	NN	I-NP	O
4	4	CD	I-NP	O
.	.	.	O	O

Pulmonary	Pulmonary	JJ	B-ADJP	O
.	.	.	O	O

Given	Give	VBN	B-PP	O
the	the	DT	B-NP	O
fact	fact	NN	I-NP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
normal	normal	JJ	I-NP	O
pulmonary	pulmonary	JJ	I-NP	O
capillary	capillary	JJ	I-NP	O
wedge	wedge	NN	I-NP	O
pressure	pressure	NN	I-NP	O
and	and	CC	O	O
elevated	elevated	JJ	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
artery	artery	NN	I-NP	O
pressures	pressure	NNS	I-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
brief	brief	JJ	I-NP	O
investigation	investigation	NN	I-NP	O
of	of	IN	B-PP	O
pulmonary	pulmonary	JJ	B-NP	O
parenchymal	parenchymal	JJ	I-NP	O
disease	disease	NN	I-NP	O
was	be	VBD	B-VP	O
undertaken	undertake	VBN	I-VP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
high	high	JJ	I-NP	O
resolution	resolution	NN	I-NP	O
chest	chest	NN	I-NP	O
CT	CT	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
showed	show	VBD	B-VP	O
mild	mild	JJ	B-NP	O
ground	ground	NN	I-NP	O
glass	glass	NN	I-NP	O
infiltrate	infiltrate	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
bases	base	NNS	I-NP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
pulmonary	pulmonary	JJ	B-NP	O
edema	edema	NN	I-NP	O
and	and	CC	O	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
interstitial	interstitial	JJ	B-NP	O
process	process	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
also	also	RB	B-ADVP	O
had	have	VBD	B-VP	O
pulmonary	pulmonary	JJ	B-NP	O
function	function	NN	I-NP	O
tests	test	NNS	I-NP	O
.	.	.	O	O

Pulmonary	Pulmonary	JJ	B-NP	O
function	function	NN	I-NP	O
tests	test	NNS	I-NP	O
revealed	reveal	VBD	B-VP	O
an	an	DT	B-NP	O
FVC	FVC	NN	I-NP	O
of	of	IN	B-PP	O
1.88	1.88	CD	B-NP	O
liters	liter	NNS	I-NP	O
and	and	CC	O	O
an	an	DT	B-NP	O
FEV1	FEV1	NN	I-NP	O
of	of	IN	B-PP	O
1.33	1.33	CD	B-NP	O
liters	liter	NNS	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
gives	give	VBZ	B-VP	O
an	an	DT	B-NP	O
FEV1	FEV1	NN	I-NP	O
to	to	TO	B-PP	O
FVC	FVC	NN	B-NP	O
percent	percent	NN	I-NP	O
of	of	IN	B-PP	O
71	71	CD	B-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
both	both	DT	B-NP	O
decreased	decrease	VBN	I-NP	O
FVC	FVC	NN	I-NP	O
and	and	CC	I-NP	O
FEV1	FEV1	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
an	an	DT	B-NP	O
FEV1	FEV1	NN	I-NP	O
and	and	CC	I-NP	O
FVC	FVC	NN	I-NP	O
percent	percent	NN	I-NP	O
that	that	WDT	B-NP	O
is	be	VBZ	B-VP	O
most	most	RBS	B-ADJP	O
consistent	consistent	JJ	I-ADJP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
mild	mild	JJ	I-NP	O
restriction	restriction	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
lung	lung	NN	I-NP	O
volumes	volume	NNS	I-NP	O
are	be	VBP	B-VP	O
approximately	approximately	RB	B-NP	O
50	50	CD	I-NP	O
%	%	NN	I-NP	O
predicted	predict	VBN	B-VP	O
suggestive	suggestive	JJ	B-ADJP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
restrictive	restrictive	JJ	I-NP	O
process	process	NN	I-NP	O
and	and	CC	O	O
his	his	PRP$	B-NP	O
DLCO	DLCO	NNP	I-NP	O
both	both	DT	B-NP	O
corrected	correct	VBD	B-VP	O
and	and	CC	O	O
uncorrected	uncorrected	JJ	B-NP	O
are	be	VBP	B-VP	O
50	50	CD	B-NP	O
%	%	NN	I-NP	O
predicted	predict	VBN	B-ADJP	O
.	.	.	O	O

His	His	PRP$	B-NP	B-protein
corrected	correct	VBN	I-NP	O
DLCO	DLCO	NNP	I-NP	O
is	be	VBZ	B-VP	O
13.5	13.5	CD	B-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
is	be	VBZ	B-VP	O
unclear	unclear	JJ	B-ADJP	O
if	if	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
underlying	underlie	VBG	I-VP	O
restrictive	restrictive	JJ	B-NP	O
lung	lung	NN	I-NP	O
disease	disease	NN	I-NP	O
given	give	VBN	B-VP	O
the	the	DT	B-NP	O
absence	absence	NN	I-NP	O
of	of	IN	B-PP	O
definitive	definitive	JJ	B-NP	O
interstitial	interstitial	JJ	I-NP	O
process	process	NN	I-NP	O
on	on	IN	B-PP	O
high	high	JJ	B-NP	O
resolution	resolution	NN	I-NP	O
chest	chest	NN	I-NP	O
CT.	CT.	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
more	more	RBR	I-NP	O
likely	likely	JJ	I-NP	O
explanation	explanation	NN	I-NP	O
for	for	IN	B-PP	O
these	these	DT	B-NP	O
findings	finding	NNS	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
residual	residual	JJ	I-NP	O
pulmonary	pulmonary	JJ	I-NP	O
edema	edema	NN	I-NP	O
relating	relate	VBG	B-VP	O
to	to	TO	B-PP	O
inadequate	inadequate	JJ	B-NP	O
diuresis	diuresis	NN	I-NP	O
with	with	IN	B-PP	O
his	his	PRP$	B-NP	O
congestive	congestive	JJ	I-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
sating	sate	VBG	I-VP	O
98	98	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Endocrine	Endocrine	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
very	very	RB	B-ADJP	O
difficult	difficult	JJ	I-ADJP	O
to	to	TO	B-VP	O
control	control	VB	I-VP	O
diabetes	diabetes	NN	B-NP	O
mellitus	mellitus	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
both	both	CC	O	O
NPH	NPH	NN	B-NP	B-protein
and	and	CC	O	O
Lispro	Lispro	NN	B-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
while	while	IN	B-SBAR	O
in	in	IN	B-PP	O
house	house	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
briefly	briefly	RB	B-ADJP	O
hypoglycemic	hypoglycemic	JJ	I-ADJP	O
during	during	IN	B-PP	O
his	his	PRP$	B-NP	O
initial	initial	JJ	I-NP	O
hospital	hospital	NN	I-NP	O
course	course	NN	I-NP	O
because	because	IN	B-PP	O
of	of	IN	I-PP	O
a	a	DT	B-NP	O
urinary	urinary	JJ	I-NP	O
tract	tract	NN	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
resolved	resolve	VBD	B-VP	O
after	after	IN	B-PP	O
approximately	approximately	RB	B-NP	O
24	24	CD	I-NP	O
hours	hour	NNS	I-NP	O
of	of	IN	B-PP	O
holding	hold	VBG	B-VP	O
his	his	PRP$	B-NP	O
long-acting	long-acting	JJ	I-NP	B-protein
insulin	insulin	NN	I-NP	I-protein
and	and	CC	O	O
giving	give	VBG	B-VP	O
him	him	PRP	B-NP	O
glucose	glucose	NN	B-NP	O
replacement	replacement	NN	I-NP	O
therapy	therapy	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
euglycemic	euglycemic	JJ	B-ADJP	O
on	on	IN	B-PP	O
15	15	CD	B-NP	O
and	and	CC	I-NP	O
10	10	CD	I-NP	O
of	of	IN	B-PP	O
NPH	NPH	NN	B-NP	B-protein
in	in	IN	B-PP	O
the	the	DT	B-NP	O
a.m.	a.m.	NN	I-NP	O
and	and	CC	O	O
p.m.	p.m.	RB	O	O
respectively	respectively	RB	O	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
a	a	DT	B-NP	O
Lispro	Lispro	NNP	I-NP	O
scale	scale	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

Furthermore	Furthermore	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
TSH	TSH	NN	I-NP	O
of	of	IN	B-PP	O
0.219	0.219	CD	B-NP	O
as	as	RB	I-NP	O
well	well	RB	I-NP	O
as	as	IN	I-NP	O
a	a	DT	B-NP	O
normal	normal	JJ	I-NP	O
T4	T4	NN	I-NP	O
,	,	,	O	O
this	this	DT	B-NP	O
is	be	VBZ	B-VP	O
suggestive	suggestive	JJ	B-ADJP	O
of	of	IN	B-PP	O
clinical	clinical	JJ	B-NP	O
hypothyroidism	hypothyroidism	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
over	over	IN	B-PP	O
replacement	replacement	NN	B-NP	O
with	with	IN	B-PP	O
Synthroid	Synthroid	JJ	B-ADJP	O
such	such	JJ	B-PP	O
as	as	IN	I-PP	O
maintenance	maintenance	NN	B-NP	O
Synthroid	Synthroid	JJ	I-NP	O
dose	dose	NN	I-NP	O
is	be	VBZ	B-VP	O
decreased	decrease	VBN	I-VP	O
from	from	IN	B-PP	O
75	75	CD	B-NP	O
mcg	mcg	NN	I-NP	O
to	to	TO	B-PP	O
60.5	60.5	CD	B-NP	O
mcg	mcg	NN	I-NP	O
and	and	CC	O	O
we	we	PRP	B-NP	O
recommend	recommend	VBP	B-VP	O
a	a	DT	B-NP	O
TSH	TSH	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
checked	check	VBN	I-VP	O
in	in	IN	B-PP	O
late	late	JJ	B-NP	O
February	February	NNP	I-NP	O
2004	2004	CD	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Renal	Renal	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
baseline	baseline	NN	B-NP	O
chronic	chronic	JJ	I-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
presumably	presumably	RB	B-ADJP	O
due	due	JJ	I-ADJP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
combination	combination	NN	I-NP	O
of	of	IN	B-PP	O
diabetes	diabetes	NN	B-NP	O
and	and	CC	I-NP	O
hypertension	hypertension	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
had	have	VBN	I-VP	O
adverse	adverse	JJ	B-NP	O
reaction	reaction	NN	I-NP	O
to	to	TO	B-PP	O
contrast	contrast	NN	B-NP	O
dye	dye	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
creatinine	creatinine	NN	I-NP	O
bump	bump	NN	I-NP	O
to	to	TO	B-PP	O
nearly	nearly	RB	B-NP	O
7	7	CD	I-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
wanted	want	VBD	B-VP	O
to	to	TO	I-VP	O
avoid	avoid	VB	I-VP	O
as	as	IN	B-NP	O
much	much	JJ	I-NP	O
contrast	contrast	NN	I-NP	O
dye	dye	NN	I-NP	O
as	as	IN	B-PP	O
possible	possible	JJ	B-ADJP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
hospital	hospital	NN	I-NP	O
stay	stay	NN	I-NP	O
because	because	IN	B-PP	O
of	of	IN	I-PP	O
his	his	PRP$	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
ended	end	VBD	B-VP	O
up	up	RP	B-PRT	O
re-dosing	re-dose	VBG	B-VP	O
his	his	PRP$	B-NP	O
digoxin	digoxin	NN	I-NP	O
to	to	TO	B-PP	O
three	three	CD	B-NP	O
times	time	NNS	I-NP	O
weekly	weekly	RB	B-ADVP	O
from	from	IN	B-PP	O
every	every	DT	B-NP	O
other	other	JJ	I-NP	O
day	day	NN	I-NP	O
because	because	IN	B-PP	O
of	of	IN	I-PP	O
the	the	DT	B-NP	O
dig	dig	NN	I-NP	O
level	level	NN	I-NP	O
of	of	IN	B-PP	O
0.19	0.19	CD	B-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
was	be	VBD	B-VP	O
2.7	2.7	CD	B-NP	O
and	and	CC	O	O
falling	fall	VBG	B-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
and	and	CC	O	O
his	his	PRP$	B-NP	O
BUN	BUN	NN	I-NP	B-protein
was	be	VBD	B-VP	O
67	67	CD	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
making	make	VBG	I-VP	O
good	good	JJ	B-NP	O
urine	urine	NN	I-NP	O
and	and	CC	O	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
residual	residual	JJ	B-NP	O
urinary	urinary	JJ	I-NP	O
tract	tract	NN	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

Upon	Upon	IN	B-PP	O
presentation	presentation	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
after	after	IN	B-PP	O
a	a	DT	B-NP	O
Foley	Foley	NNP	I-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
became	become	VBD	B-VP	O
a	a	DT	B-NP	O
little	little	JJ	I-NP	O
delirious	delirious	JJ	B-ADJP	O
and	and	CC	I-ADJP	O
hypoglycemic	hypoglycemic	JJ	I-ADJP	O
.	.	.	O	O

Urine	Urine	NN	B-NP	B-cell_line
cultures	culture	NNS	I-NP	I-cell_line
grew	grow	VBD	B-VP	O
out	out	RP	B-PRT	O
greater	great	JJR	B-NP	O
than	than	IN	I-NP	O
100	100	CD	I-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
colonies	colony	NNS	I-NP	O
of	of	IN	B-PP	O
Serratia	Serratia	NNP	B-NP	O
marcescens	marcescens	NNP	I-NP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
a	a	DT	B-NP	O
14-day	14-day	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
renally	renally	RB	B-NP	O
dosed	dose	VBN	I-NP	O
levofloxacin	levofloxacin	NN	I-NP	O
with	with	IN	B-PP	O
good	good	JJ	B-NP	O
resolution	resolution	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
symptoms	symptom	NNS	I-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Neuropsych	Neuropsych	UH	B-INTJ	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
depression	depression	NN	B-NP	O
and	and	CC	O	O
had	have	VBD	B-VP	O
some	some	DT	B-NP	O
mild	mild	JJ	I-NP	O
delirium	delirium	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
urinary	urinary	JJ	B-NP	O
tract	tract	NN	I-NP	O
infection	infection	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
resolved	resolve	VBD	B-VP	O
with	with	IN	B-PP	O
p.r.n.	p.r.n.	NN	B-NP	O
Zyprexa	Zyprexa	NNP	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
treating	treat	VBG	B-VP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
underlying	underlying	JJ	I-NP	O
condition	condition	NN	I-NP	O
.	.	.	O	O

Psychiatric	Psychiatric	NNP	B-NP	O
Service	Service	NNP	I-NP	O
was	be	VBD	B-VP	O
consulted	consult	VBN	I-VP	O
and	and	CC	O	O
felt	feel	VBD	B-VP	O
like	like	IN	B-SBAR	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
resolving	resolve	VBG	I-NP	O
medical	medical	JJ	I-NP	O
delirium	delirium	NN	I-NP	O
and	and	CC	O	O
there	there	EX	B-NP	O
is	be	VBZ	B-VP	O
no	no	DT	B-NP	O
indication	indication	NN	I-NP	O
for	for	IN	B-PP	O
further	further	JJ	B-NP	O
pharmacal	pharmacal	JJ	I-NP	O
or	or	CC	I-NP	O
psychodynamic	psychodynamic	JJ	I-NP	O
therapy	therapy	NN	I-NP	O
at	at	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
.	.	.	O	O

-LRB-	-LRB-	SYM	O	O
His	His	PRP$	B-NP	O
mild	mild	JJ	I-NP	O
subclinical	subclinical	JJ	I-NP	O
hyperthyroidism	hyperthyroidism	NN	I-NP	O
may	may	MD	B-VP	O
have	have	VB	I-VP	O
contributed	contribute	VBN	I-VP	O
to	to	TO	B-PP	O
his	his	PRP$	B-NP	O
low	low	JJ	I-NP	O
mood	mood	NN	I-NP	O
as	as	IN	B-PP	O
apathetic	apathetic	JJ	B-NP	O
hyperthyroidism	hyperthyroidism	NN	I-NP	O
in	in	IN	B-PP	O
a	a	DT	B-NP	O
gentleman	gentleman	NN	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
age	age	NN	I-NP	O
is	be	VBZ	B-VP	O
not	not	RB	O	O
uncommon	uncommon	JJ	B-ADJP	O
.	.	.	O	O
-RRB-	-RRB-	NNP	B-NP	O

9	9	CD	B-NP	O
.	.	.	O	O

Prophylaxis	Prophylaxis	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
Nexium	Nexium	NN	B-NP	O
for	for	IN	B-PP	O
GI	GI	NN	B-NP	O
prophylaxis	prophylaxis	NN	I-NP	O
and	and	CC	O	O
subcutaneous	subcutaneous	JJ	B-NP	O
heparin	heparin	NN	I-NP	O
for	for	IN	B-PP	O
DVT	DVT	NN	B-NP	O
prophylaxis	prophylaxis	NN	I-NP	O
.	.	.	O	O

CODE	CODE	NN	B-NP	O
STATUS	STATUS	NNS	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
full	full	JJ	B-NP	O
code	code	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
consulted	consult	VBN	I-VP	O
by	by	IN	B-PP	O
both	both	CC	O	O
Physical	Physical	JJ	B-NP	O
Therapy	Therapy	NN	I-NP	O
and	and	CC	O	O
Occupational	Occupational	JJ	B-NP	O
Therapy	Therapy	NN	I-NP	O
who	who	WP	B-NP	O
felt	feel	VBD	B-VP	O
that	that	DT	B-NP	O
acute	acute	JJ	I-NP	O
rehabilitation	rehabilitation	NN	I-NP	O
would	would	MD	B-VP	O
be	be	VB	I-VP	O
warranted	warrant	VBN	I-VP	O
at	at	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
.	.	.	O	O

DISPOSITION	DISPOSITION	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
in	in	IN	B-PP	O
stable	stable	JJ	B-NP	O
condition	condition	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
chest	chest	NN	B-NP	O
pain	pain	NN	I-NP	O
free	free	JJ	B-ADJP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Irbar	Irbar	NNP	I-NP	O
Medical	Medical	NNP	I-NP	O
Center	Center	NNP	I-NP	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
health	health	NN	I-NP	O
care	care	NN	I-NP	O
proxy	proxy	NN	I-NP	O
is	be	VBZ	B-VP	O
his	his	PRP$	B-NP	O
wife	wife	NN	I-NP	O
,	,	,	O	O
Mrs.	Mrs.	NNP	B-NP	O
Blake	Blake	NNP	I-NP	O
Maker	Maker	NNP	I-NP	O
,	,	,	O	O
whose	whose	WP$	B-NP	O
phone	phone	NN	I-NP	O
number	number	NN	I-NP	O
is	be	VBZ	B-VP	O
-LRB-	-LRB-	SYM	B-ADJP	O
158	158	CD	B-NP	O
-RRB-	-RRB-	SYM	I-NP	O
000-3426	000-3426	CD	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
followed	follow	VBN	I-VP	O
by	by	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Valentine	Valentine	NNP	I-NP	O
Cloer	Cloer	NNP	I-NP	O
at	at	IN	B-PP	O
As	As	NNP	B-NP	O
Medical	Medical	NNP	I-NP	O
Center	Center	NNP	I-NP	O
Schedule	Schedule	NNP	I-NP	O
appointments	appointment	NNS	I-NP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Jo	Jo	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
703	703	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
219-1739	219-1739	CD	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
physician	physician	NN	I-NP	O
is	be	VBZ	B-VP	O
Dr.	Dr.	NNP	B-NP	O
Arthur	Arthur	NNP	I-NP	O
Widener	Widener	NNP	I-NP	O
at	at	IN	B-PP	O
-LRB-	-LRB-	NNP	B-NP	O
865	865	CD	I-NP	O
-RRB-	-RRB-	NNP	B-NP	O
227-2987	227-2987	CD	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
fluid-restricted	fluid-restricted	JJ	I-NP	O
diet	diet	NN	I-NP	O
of	of	IN	B-PP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
2	2	CD	I-NP	O
liters	liter	NNS	I-NP	O
of	of	IN	B-PP	O
fluid	fluid	NN	B-NP	O
total	total	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
should	should	MD	B-VP	O
have	have	VB	I-VP	O
low-cholesterol	low-cholesterol	JJ	B-NP	O
,	,	,	I-NP	O
low-saturated	low-saturated	JJ	I-NP	O
fat	fat	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
a	a	DT	B-NP	O
diabetic	diabetic	JJ	I-NP	O
diet	diet	NN	I-NP	O
with	with	IN	B-PP	O
ADA	ADA	NN	B-NP	O
2100	2100	CD	I-NP	O
calories	calorie	NNS	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
should	should	MD	B-VP	O
also	also	RB	I-VP	O
be	be	VB	I-VP	O
sodium	sodium	NN	B-NP	O
restricted	restricted	JJ	B-ADJP	O
to	to	TO	B-PP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
2	2	CD	I-NP	O
g	g	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

Activity	Activity	NN	B-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
guided	guide	VBN	I-VP	O
by	by	IN	B-PP	O
Physical	Physical	JJ	B-NP	O
Therapy	Therapy	NN	I-NP	O
at	at	IN	B-PP	O
none	none	NN	B-NP	O
TO	TO	NN	I-NP	O
DO	DO	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Titrate	Titrate	NN	B-NP	O
amlodipine	amlodipine	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
tolerated	tolerate	VBN	I-VP	O
up	up	IN	B-NP	O
to	to	TO	I-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
amlodipine	amlodipine	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Consider	Consider	VB	B-VP	O
outpatient	outpatient	NN	B-NP	O
trial	trial	NN	I-NP	O
of	of	IN	B-PP	O
ACE	ACE	NN	B-NP	O
inhibitor	inhibitor	NN	I-NP	O
or	or	CC	I-NP	O
ARB	ARB	NN	I-NP	B-protein
in	in	IN	B-PP	O
the	the	DT	B-NP	O
future	future	NN	I-NP	O
with	with	IN	B-PP	O
close	close	JJ	B-NP	O
monitoring	monitoring	NN	I-NP	O
of	of	IN	B-PP	O
potassium	potassium	NN	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Recheck	Recheck	NN	B-NP	O
TSH	TSH	NN	I-NP	O
late	late	JJ	B-NP	O
February	February	NNP	I-NP	O
2004	2004	CD	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Complete	Complete	JJ	B-NP	O
former	former	JJ	I-NP	O
days	day	NNS	I-NP	O
of	of	IN	B-PP	O
antibiotics	antibiotic	NNS	B-NP	O
for	for	IN	B-PP	O
Serratia	Serratia	NNP	B-NP	O
urinary	urinary	JJ	I-NP	O
tract	tract	NN	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
CONDITION	CONDITION	NN	I-NP	O
:	:	:	O	O
Stable	Stable	JJ	B-ADJP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Tylenol	Tylenol	NN	B-NP	O
650	650	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
4h	4h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-NP	O
headache	headache	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Vitamin	Vitamin	NN	B-NP	B-protein
C	C	NN	I-NP	I-protein
500	500	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	FW	B-NP	I-protein
t.i.d.	t.i.d.	FW	I-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
to	to	TO	B-VP	O
help	help	VB	I-VP	O
with	with	IN	B-PP	O
iron	iron	NN	B-NP	B-protein
absorption	absorption	NN	I-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Enteric-coated	Enteric-coated	JJ	B-NP	O
aspirin	aspirin	NN	I-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
4	4	CD	I-NP	O
.	.	.	O	O

Digoxin	Digoxin	NN	B-NP	O
0.125	0.125	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.	q.	NN	I-NP	O
Monday	Monday	NNP	B-NP	O
,	,	,	O	O
Wednesday	Wednesday	NNP	B-NP	O
and	and	CC	O	O
Friday	Friday	NNP	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
6	6	CD	I-NP	O
.	.	.	O	O

Procrit	Procrit	NNP	B-NP	O
40	40	CD	I-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
q.	q.	VBP	B-VP	O
2	2	CD	B-NP	O
weeks	week	NNS	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
for	for	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
disease	disease	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Iron	Iron	NN	B-NP	B-protein
-LRB-	-LRB-	HYPH	I-NP	O
ferrous	ferrous	JJ	I-NP	B-protein
sulfate	sulfate	NN	I-NP	I-protein
-RRB-	-RRB-	HYPH	B-NP	I-protein
325	325	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
t.i.d.	t.i.d.	NN	I-NP	I-protein
8	8	CD	I-NP	I-protein
.	.	.	O	O

Lasix	Lasix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
9	9	CD	I-NP	O
.	.	.	O	O

Heparin	Heparin	NN	B-NP	B-protein
5000	5000	CD	B-NP	I-protein
units	unit	NNS	I-NP	I-protein
subcutaneously	subcutaneously	RB	B-ADVP	O
t.i.d.	t.i.d.	RB	B-NP	O
10	10	CD	I-NP	O
.	.	.	O	O

Hydralazine	Hydralazine	NN	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
q.i.d.	q.i.d.	FW	I-ADVP	O
,	,	,	O	O
hold	hold	VBP	B-VP	O
for	for	IN	B-PP	O
systolic	systolic	JJ	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
less	less	JJR	B-ADJP	O
than	than	IN	B-PP	O
100	100	CD	B-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

NPH	NPH	NNP	B-NP	O
Humulin	Humulin	NNP	I-NP	O
Insulin	Insulin	NNP	I-NP	O
15	15	CD	B-NP	O
units	unit	NNS	I-NP	O
q.a.m.	q.a.m.	RB	B-ADVP	O
,	,	,	O	O
10	10	CD	B-NP	O
units	unit	NNS	I-NP	O
q.p.m.	q.p.m.	RB	B-ADVP	O
subcutaneously	subcutaneously	RB	I-ADVP	O
,	,	,	O	O
hold	hold	VBP	B-VP	O
if	if	IN	B-SBAR	O
fasting	fast	VBG	B-VP	O
sugars	sugar	NNS	B-NP	O
less	less	JJR	B-ADJP	O
than	than	IN	B-PP	O
100	100	CD	B-NP	O
,	,	,	O	O
please	please	NN	B-NP	O
give	give	VBP	B-VP	O
half	half	JJ	B-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
n.p.o.	n.p.o.	NN	B-NP	O
12	12	CD	I-NP	O
.	.	.	O	O

Isordil	Isordil	NN	B-NP	O
60	60	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
13	13	CD	I-NP	O
.	.	.	O	O

Lactulose	Lactulose	RB	B-NP	O
30	30	CD	I-NP	O
ml	ml	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
q.i.d.	q.i.d.	FW	I-NP	O
-LRB-	-LRB-	FW	I-NP	O
hold	hold	VBP	B-VP	O
if	if	IN	B-SBAR	O
diarrhea	diarrhea	NN	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
.	.	.	O	O

14	14	CD	B-NP	O
.	.	.	O	O

Synthroid	Synthroid	JJ	B-NP	O
62.5	62.5	CD	I-NP	O
mcg	mcg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
recheck	recheck	NN	I-NP	O
TSH	TSH	NN	I-NP	O
late	late	JJ	B-NP	O
February	February	NNP	I-NP	O
2004	2004	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
.	.	.	O	O

15	15	CD	B-NP	O
.	.	.	O	O

Milk	Milk	NN	B-NP	O
of	of	IN	B-PP	O
magnesia	magnesia	NN	B-NP	O
30	30	CD	I-NP	O
ml	ml	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
q.d.	q.d.	FW	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
constipation	constipation	NN	I-NP	O
.	.	.	O	O

16	16	CD	B-NP	O
.	.	.	O	O

Nitroglycerin	Nitroglycerin	NN	B-NP	O
0.4	0.4	CD	I-NP	O
mg	mg	NN	I-NP	O
one	one	CD	B-NP	O
tablet	tablet	NN	I-NP	B-protein
subcutaneously	subcutaneously	RB	B-NP	I-protein
q.	q.	RB	I-NP	I-protein
5	5	CD	I-NP	I-protein
minutes	minute	NNS	I-NP	I-protein
x	x	SYM	B-NP	I-protein
3	3	CD	I-NP	I-protein
p.r.n.	p.r.n.	NN	I-NP	I-protein
chest	chest	NN	I-NP	I-protein
pain	pain	NN	I-NP	I-protein
,	,	,	O	O
hold	hold	VBP	B-VP	O
if	if	IN	B-SBAR	O
SVT	SVT	NN	B-NP	O
less	less	JJR	B-ADJP	O
than	than	IN	B-PP	O
100	100	CD	B-NP	O
.	.	.	O	O

17	17	CD	B-NP	O
.	.	.	O	O

Senna	Senna	NNP	B-NP	O
two	two	CD	I-NP	O
tablets	tablet	NNS	I-NP	O
p.o.	p.o.	FW	I-NP	O
b.i.d.	b.i.d.	FW	I-NP	O
p.r.n.	p.r.n.	FW	I-NP	O
constipation	constipation	NN	I-NP	O
.	.	.	O	O

18	18	CD	B-NP	O
.	.	.	O	O

Proscar	Proscar	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
19	19	CD	I-NP	O
.	.	.	O	O

Zocor	Zocor	NN	B-NP	O
80	80	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
20	20	CD	I-NP	O
.	.	.	O	O

Amlodipine	Amlodipine	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.d.	q.d.	NN	I-NP	O
,	,	,	O	O
hold	hold	VBP	B-VP	O
if	if	IN	B-SBAR	O
systolic	systolic	JJ	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
less	less	JJR	B-ADJP	O
than	than	IN	B-PP	O
100	100	CD	B-NP	O
.	.	.	O	O

21	21	CD	B-NP	O
.	.	.	O	O

Zyprexa	Zyprexa	NN	B-NP	O
2.5	2.5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
q.h.s.	q.h.s.	FW	I-NP	O
p.r.n.	p.r.n.	FW	I-NP	O
insomnia	insomnia	NN	I-NP	O
.	.	.	O	O

22	22	CD	B-NP	O
.	.	.	O	O

Carvedilol	Carvedilol	NN	B-NP	O
3.125	3.125	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
23	23	CD	I-NP	O
.	.	.	O	O

Levofloxacin	Levofloxacin	NN	B-NP	O
250	250	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
48h	48h	NN	I-NP	O
.	.	.	O	O

x	x	SYM	O	O
2	2	CD	B-NP	O
more	more	JJR	I-NP	O
doses	dose	NNS	I-NP	O
-LRB-	-LRB-	.	O	O
4	4	CD	B-NP	O
more	more	JJR	I-NP	O
days	day	NNS	I-NP	O
total	total	JJ	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
.	.	.	O	O

24	24	CD	B-NP	O
.	.	.	O	O

Nephrocaps	Nephrocaps	RB	B-NP	O
one	one	CD	I-NP	O
tablet	tablet	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
25	25	CD	I-NP	O
.	.	.	O	O

Lispro	Lispro	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
Insulin	Insulin	NNP	I-NP	O
Lispro	Lispro	NNP	I-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	B-protein
-RRB-	-RRB-	NN	I-NP	I-protein
subcutaneously	subcutaneously	RB	B-ADVP	O
q.a.c.	q.a.c.	RB	I-ADVP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
is	be	VBZ	B-VP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
125	125	CD	I-NP	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
0	0	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
is	be	VBZ	B-VP	O
125-150	125-150	CD	B-NP	O
then	then	RB	I-NP	O
give	give	VB	B-VP	O
2	2	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
is	be	VBZ	B-VP	O
151-200	151-200	CD	B-NP	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
3	3	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
is	be	VBZ	B-VP	O
201-250	201-250	CD	B-NP	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
4	4	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
is	be	VBZ	B-VP	O
251-300	251-300	CD	B-NP	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
6	6	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
is	be	VBZ	B-VP	O
301-350	301-350	CD	B-NP	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
8	8	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
,	,	,	O	O
if	if	IN	B-SBAR	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
is	be	VBZ	B-VP	O
351-400	351-400	CD	B-NP	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
10	10	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
and	and	CC	O	O
notify	notify	VB	B-VP	O
covering	cover	VBG	I-VP	O
physician	physician	NN	B-NP	O
.	.	.	O	O

26	26	CD	B-NP	O
.	.	.	O	O

Flomax	Flomax	NN	B-NP	O
0.4	0.4	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
27	27	CD	I-NP	O
.	.	.	O	O

Nexium	Nexium	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
28	28	CD	I-NP	O
.	.	.	O	O

Maalox	Maalox	NNP	B-NP	O
1-2	1-2	CD	I-NP	O
tablets	tablet	NNS	I-NP	O
p.o.	p.o.	FW	B-NP	O
q.	q.	FW	I-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-NP	O
upset	upset	JJ	I-NP	O
stomach	stomach	NN	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
0-3309193	0-3309193	CD	B-NP	O
EMSSten	EMSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
VAISMAN	VAISMAN	NNP	B-NP	O
,	,	,	O	O
NOE	NOE	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
STALFORD	STALFORD	NN	B-NP	O
,	,	,	O	O
CHONG	CHONG	NNP	B-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
6500413	6500413	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
9/23/04	9/23/04	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
9/23/04	9/23/04	CD	B-NP	O

